Lung Function Response to 12-week Treatment with Combined Inhalation of Long-acting β2 Agonist and Glucocorticoid According to ADRB2 Polymorphism in Patients with Chronic Obstructive Pulmonary Disease

[1]  E. Simons.  Effect of ADRB2 Polymorphisms on Response to Longacting β2-Agonist Therapy: A Pharmacogenetic Analysis of Two Randomised Studies , 2008, Pediatrics.

[2]  M. Hasegawa,et al.  Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. , 2007, Chest.

[3]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[4]  Deborah A Meyers,et al.  Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. , 2006, American journal of respiratory and critical care medicine.

[5]  L. Edwards,et al.  Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. , 2006, The Journal of allergy and clinical immunology.

[6]  D. Sin,et al.  Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. , 2006, European journal of pharmacology.

[7]  Vernon M. Chinchilli,et al.  β-Adrenergic Receptor Polymorphisms and Response to Salmeterol , 2006 .

[8]  Bruce D. Johnson,et al.  Influence of β2-Adrenergic Receptor Genotype on Airway Function During Exercise in Healthy Adults , 2006 .

[9]  M. Munakata,et al.  Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[10]  E. Israel,et al.  beta-Adrenergic receptor polymorphisms and response to salmeterol. , 2006, American journal of respiratory and critical care medicine.

[11]  M. Munakata,et al.  Molecular-Based Haplotype Analysis of the β 2-Adrenergic Receptor Gene (ADRB2) in Japanese Asthmatic and Non-Asthmatic Subjects. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[12]  P. Jones,et al.  Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease , 2005, Thorax.

[13]  E. Silverman,et al.  Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. , 2005, American journal of respiratory and critical care medicine.

[14]  K. Min,et al.  Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene. , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[15]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[16]  M. Cazzola,et al.  Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. , 2004, Chest.

[17]  G. Keating,et al.  Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease. , 2004, Drugs.

[18]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[19]  R. Kim,et al.  The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. , 2001, The New England journal of medicine.

[20]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. Silverman,et al.  The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.

[22]  P. Ghahramani,et al.  Influence of genetic polymorphisms in the β2-adrenoceptor on desensitization in human lung mast cells , 2000 .

[23]  D. Thomason,et al.  Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics , 1999, Clinical pharmacology and therapeutics.

[24]  R. Hancox,et al.  Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. , 1998, The European respiratory journal.

[25]  R. Erickson,et al.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.

[26]  S. Liggett.  Polymorphisms of the beta2-adrenergic receptor and asthma. , 1997, American journal of respiratory and critical care medicine.

[27]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[28]  I. Hall,et al.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.

[29]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[30]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.

[31]  Buist As.  Standardization of spirometry. , 1987 .